Enhertu, G-tec will benefit from new govn't plan
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.12.23 05:50:55
가나다라
0
Enthertu’s reimb passes pharmacoeconomic évaluations and makes way
New drug G-tec will likely be eligible for preferential drug pricing as a new botanical drug

According to the ‘Plan for the compensation of the innovative value of new drugs’ that the government announced on the 22nd, the breast cancer treatment ‘Enhertu (Daiichi Sankyo-AstraZeneca),’ and the new gastrointestinal botanical drug ‘G-tec (Chong Kund Dang)’ are being regarded as immediate beneficiaries.
In the case of Enhertu, it is expected to receive a reimbursement and make way for its reimbursement according to the benefit plan for innovative new drugs according to preferential price awarded to new innovative drugs.' G-tec will receive preferential treatment as a new botanical drug.
The burden of drug price cuts for new products produced by innovative pharmaceutical compan
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)